Nat commun:从两个主要的来源的肾癌细胞系分析可以成功的进行基于基因组的细胞系选择

2017-05-16 AlexYang MedSci原创

癌细胞系的利用可以被相似性的内源性肿瘤细胞影响。最近,有研究人员将来自癌症细胞系百科和COSMIC细胞系工程的来源于肾的65个细胞系的基因组数据与来源于肿瘤基因组计划的3种肾癌细胞亚型进行了比较,这3中肾细胞亚型分别为:肾透明细胞癌(ccRCC),肾乳头状细胞癌(pRCC)和肾难染性细胞癌(chRCC)。研究发现,聚类拷贝数改变表明了大多数细胞系类似于ccRCC,有一些(包括一些经常被用于ccRC

癌细胞系的利用可以被相似性的内源性肿瘤细胞影响。最近,有研究人员将来自癌症细胞系百科和COSMIC细胞系工程的来源于肾的65个细胞系的基因组数据与来源于肿瘤基因组计划的3种肾癌细胞亚型进行了比较,这3中肾细胞亚型分别为:肾透明细胞癌(ccRCC),肾乳头状细胞癌(pRCC)和肾难染性细胞癌(chRCC)。

研究发现,聚类拷贝数改变表明了大多数细胞系类似于ccRCC,有一些(包括一些经常被用于ccRCC模型)细胞系类似于pRCC,但是没有细胞系类似于chRCC。人类ccRCC肿瘤与细胞系聚类表现了更加具有侵入性疾病的临床和基因组特性,表明了细胞系能够最好的代表侵入性肿瘤。研究人员通过数据库之间的一致性,分层分析了重要肾癌基因的突变和拷贝数改变,并且将细胞系基于基因表达分类为懒惰性亚型和侵入性亚型。最后,研究人员指出,这些结果可以帮助研究者分析合适的肾癌细胞系。

原始出处:

Rileen Sinha, Andrew G. Winer, Michael Chevinsky et al. Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. Nat commun. 10 May 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087022, encodeId=2e50208e022d6, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Oct 07 09:32:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647433, encodeId=d9a0164e43303, content=<a href='/topic/show?id=8e43e1526b6' target=_blank style='color:#2F92EE;'>#癌细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71526, encryptionId=8e43e1526b6, topicName=癌细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4723405527, createdName=xjy10, createdTime=Tue Jun 13 02:32:00 CST 2017, time=2017-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882038, encodeId=11361882038ca, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Mar 15 20:32:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252245, encodeId=363d1252245ce, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu May 18 12:32:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554008, encodeId=c0b61554008e8, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Thu May 18 12:32:00 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
    2017-10-07 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087022, encodeId=2e50208e022d6, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Oct 07 09:32:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647433, encodeId=d9a0164e43303, content=<a href='/topic/show?id=8e43e1526b6' target=_blank style='color:#2F92EE;'>#癌细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71526, encryptionId=8e43e1526b6, topicName=癌细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4723405527, createdName=xjy10, createdTime=Tue Jun 13 02:32:00 CST 2017, time=2017-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882038, encodeId=11361882038ca, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Mar 15 20:32:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252245, encodeId=363d1252245ce, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu May 18 12:32:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554008, encodeId=c0b61554008e8, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Thu May 18 12:32:00 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087022, encodeId=2e50208e022d6, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Oct 07 09:32:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647433, encodeId=d9a0164e43303, content=<a href='/topic/show?id=8e43e1526b6' target=_blank style='color:#2F92EE;'>#癌细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71526, encryptionId=8e43e1526b6, topicName=癌细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4723405527, createdName=xjy10, createdTime=Tue Jun 13 02:32:00 CST 2017, time=2017-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882038, encodeId=11361882038ca, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Mar 15 20:32:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252245, encodeId=363d1252245ce, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu May 18 12:32:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554008, encodeId=c0b61554008e8, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Thu May 18 12:32:00 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
    2018-03-15 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087022, encodeId=2e50208e022d6, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Oct 07 09:32:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647433, encodeId=d9a0164e43303, content=<a href='/topic/show?id=8e43e1526b6' target=_blank style='color:#2F92EE;'>#癌细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71526, encryptionId=8e43e1526b6, topicName=癌细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4723405527, createdName=xjy10, createdTime=Tue Jun 13 02:32:00 CST 2017, time=2017-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882038, encodeId=11361882038ca, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Mar 15 20:32:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252245, encodeId=363d1252245ce, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu May 18 12:32:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554008, encodeId=c0b61554008e8, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Thu May 18 12:32:00 CST 2017, time=2017-05-18, status=1, ipAttribution=)]
    2017-05-18 yxch36
  5. [GetPortalCommentsPageByObjectIdResponse(id=2087022, encodeId=2e50208e022d6, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Oct 07 09:32:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647433, encodeId=d9a0164e43303, content=<a href='/topic/show?id=8e43e1526b6' target=_blank style='color:#2F92EE;'>#癌细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71526, encryptionId=8e43e1526b6, topicName=癌细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4723405527, createdName=xjy10, createdTime=Tue Jun 13 02:32:00 CST 2017, time=2017-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882038, encodeId=11361882038ca, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Mar 15 20:32:00 CST 2018, time=2018-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252245, encodeId=363d1252245ce, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu May 18 12:32:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554008, encodeId=c0b61554008e8, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Thu May 18 12:32:00 CST 2017, time=2017-05-18, status=1, ipAttribution=)]

相关资讯

2017 NCCN临床实践指南:肾癌-证据块(2017.V2)

2016年10月31日,美国国家综合癌症网络(NCCN)发布了肾癌指南2017第1版证据块。 全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载) 

中国科学家确定肾癌治疗新靶点

12月7日从中国科学院北京基因组研究所获悉,该所研究员刘江与中科院上海药物研究所研究员蒋华良课题组、研究员杨财广课题组合作,确定了肾癌治疗的一个新靶点SPOP。这是这是中国自主研发确定的首个肾癌药物靶标,也是中国科学家从基础研究发现到药物靶标确定合作研究的成功典范。相关论文日前在线发表在《癌症细胞(Cancer Cell)》杂志上。 刘江及其科研团队与合作者们经过近十年的努力,先后发现并确

Cancer Cell:中国科学家确定肾癌治疗新靶点

记者12月7日从中国科学院北京基因组研究所获悉,该所研究员刘江与中科院上海药物研究所研究员蒋华良课题组、研究员杨财广课题组合作,确定了肾癌治疗的一个新靶点SPOP。这是这是中国自主研发确定的首个肾癌药物靶标,也是中国科学家从基础研究发现到药物靶标确定合作研究的成功典范。相关论文日前在线发表在《癌症细胞(Cancer Cell)》杂志上。刘江及其科研团队与合作者们经过近十年的努力,先后发现并确定了S

JAMA:帕唑替尼与依维莫司交替方案VS帕唑替尼连续方案在治疗转移性肾透明细胞癌患者上无显著性差异

据调研,这是首次评估交替治疗透明肾细胞癌方案的随机临床试验。本研究是一个开放标签的随机(1:1)临床研究(ROPETAR试验)。共在2012年9月至2014年4月期间于荷兰17家大型外科或学术医院入组101名初诊初期进展性转移性肾透明细胞癌患者,并接受至少一年以上的治疗。

肾癌治疗药物的过去、现在与未来

肾脏在人体中的作用不可或缺,它起到过滤人体产生的废物以及排除多余的水和盐分的作用,最常见的肾脏癌症是肾细胞癌(renal cell carcinoma,RCC),这种癌症通常是在肾小管中起源,肾小管是肾脏过滤功能的主要承载者。有超过65%的肾脏都是在还未转移时被诊断出来,这就是肾脏癌在所有癌症中预后较好的一个重要原因,未转移的癌症可以通过手术治疗而取得很好的治疗效果,手术治疗通常是切除肾脏中的

试验表明索坦辅助治疗可延长肾细胞癌患者术后无病生存期

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_